
|Videos|December 1, 2017
Dr. Voss Discusses Neoadjuvant Trials of Immunotherapy in RCC
Author(s)Martin H. Voss, MD
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).
Advertisement
Martin H. Voss, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses neoadjuvant immunotherapy trials in renal cell carcinoma (RCC).
Given the data seen in the metastatic space, the field is moving toward immunotherapy-based approaches, says Voss. This is especially true for preoperative trials in non-metastatic disease.
The phase III PROSPER RCC trial (NCT03055013) is comparing nephrectomy with or without nivolumab (Opdivo), and is currently accruing in the United States.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































